Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
AIM IMMUNOTECH INC (AIM)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$0.15-5.53%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AIM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successful capital raising through debt issuance | AIM ImmunoTech is raising capital through debt issuance to fund its operations. | Intact | Debt issuance falls significantly short of $2 million in next 2 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 16, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
AIM is a speculative clinical-development company, not a proven earnings compounder. Its thesis is in watch status: management reports progress on Ampligen, but the company remains loss-making and recent financial performance is weak.
The valuation model indicates a premium versus peers, while its low confidence limits how firmly that comparison can be read. The expectations gap is negative, and the evidence labels the priced-in picture as justified with low fragility, rather than showing a clear valuation cushion.
Near term, the earnings-miss risk is elevated, reflecting AIM’s small size and erratic recent earnings surprises. Over the multi-year view, completed enrollment and dosing in the pancreatic cancer Phase 2 trial mark progress, but revenue remains very small and losses continue; management expects key Phase 3 data in 2027.
The thesis depends on whether Ampligen’s next clinical steps produce meaningful evidence, including the planned Phase 3 trial and expected 2027 data. Near-term sector support could strengthen if healthcare bellwethers keep reporting well, while weaker jobs data or falling guidance from those companies could add pressure to cyclical healthcare names.
Over the next 1 to 3 years, AIM remains a high-risk, loss-making clinical story with a concrete trial milestone, but limited financial progress and an elevated near-term earnings risk. The multi-year view hinges chiefly on clinical execution and continued access to capital. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Recent estimate revisions show improving earnings losses, from -$1.47 to -$0.12 EPS in the current quarter. |
| Broken |
| EPS loss worsens beyond -$0.20 next quarter |
Diluted EPS: $-0.43 per share FY2026-Q2; GAAP. Published target: EPS loss improves to no worse than -$0.12 next quarter. Target period ends 2026-09-30; this observation covers 2026-Q2. Aug 7, 2026-0.43 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Progress in M&A activity through definitive agreements | A supporting condition in AIM IMMUNOTECH INC's published investment case. The stated target is At least one material definitive agreement executed. | Intact | No material definitive agreements signed within next 2 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.70 → $-0.54 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.70 | $100,000 | 1 / 1 |
| 2026-07-25 | $-0.70 | $100,000 | 1 / 1 |
| 2026-07-26 | $-0.70 | $100,000 | 1 / 1 |
| 2026-07-27 | $-0.70 | $100,000 | 1 / 1 |
| 2026-07-28 | $-0.70 | $100,000 | 1 / 1 |
| 2026-07-29 | $-0.70 | $100,000 | 1 / 1 |
| 2026-07-30 | $-0.52 | $50,000 | 1 / 2 |
| 2026-07-31 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-01 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-02 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-03 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-04 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-05 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-06 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-07 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-08 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-09 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-10 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-11 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-12 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-13 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-14 | $-0.70 | $100,000 | 1 / 1 |
| 2026-08-15 | $-0.70 | $100,000 | 1 / 1 |
| 2026-08-16 | $-0.70 | $100,000 | 1 / 1 |
| 2026-08-17 | $-0.70 | $100,000 | 1 / 1 |
| 2026-08-18 | $-0.70 | $100,000 | 1 / 1 |
| 2026-08-19 | $-0.70 | $100,000 | 1 / 1 |
| 2026-08-20 | $-0.70 | $100,000 | 1 / 1 |
| 2026-08-21 | $-0.61 | $100,000 | 1 / 1 |
| 2026-08-22 | $-0.54 | $100,000 | 1 / 1 |
| 2026-08-23 | $-0.54 | $100,000 | 1 / 1 |
| 2026-08-24 | $-0.54 | $100,000 | 1 / 1 |
| 2026-08-25 | $-0.54 | $100,000 | 1 / 1 |
| 2026-08-26 | $-0.54 | $100,000 | 1 / 1 |
| 2026-08-27 | $-0.54 | $100,000 | 1 / 1 |
| 2026-08-28 | $-0.54 | $100,000 | 1 / 1 |
| 2026-08-29 | $-0.54 | $100,000 | 1 / 1 |
| 2026-08-30 | $-0.54 | $100,000 | 1 / 1 |
| 2026-08-31 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-01 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-02 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-03 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-04 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-05 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-06 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-07 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-08 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-09 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-10 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-11 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-12 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-13 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-14 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-15 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-16 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-17 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-18 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-19 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-20 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-21 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-22 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-23 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-24 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-25 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-26 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-27 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-28 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-29 | $-0.54 | $100,000 | 1 / 1 |
| 2026-09-30 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-01 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-02 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-03 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-04 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-05 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-06 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-07 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-08 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-09 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-10 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-11 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-12 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-13 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-14 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-15 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-16 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-17 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-18 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-19 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-20 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-21 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-22 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-23 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-24 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-25 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-26 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-27 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-28 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-29 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-30 | $-0.54 | $100,000 | 1 / 1 |
| 2026-10-31 | $-0.54 | $100,000 | 1 / 1 |
| 2026-11-01 | $-0.54 | $100,000 | 1 / 1 |
| 2026-11-02 | $-0.54 | $100,000 | 1 / 1 |
| 2026-11-03 | $-0.54 | $100,000 | 1 / 1 |
| 2026-11-04 | $-0.54 | $100,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.